兩種實驗性埃博拉藥物，正在剛果拯救生命

兩種實驗性埃博拉藥物，正在剛果拯救生命

Two experimental Ebola drugs under review in the Democratic Republic of Congo already seem to be saving the lives of many affected by the deadly virus, health authorities announced.

衛(wèi)生當局宣布，正在剛果民主共和國接受審查的兩種實驗性埃博拉藥物似乎已經(jīng)挽救了許多受這種致命病毒影響的人的生命。

The two drugs — one developed by Regeneron Pharmaceuticals and the other by researchers with the US National Institutes of Health, which helped fund the study — are antibodies that block the virus.

這兩種藥物——一種是由Regeneron制藥公司開發(fā)的，另一種是由美國國立衛(wèi)生研究院的研究人員開發(fā)的，這兩個研究機構(gòu)為阻止病毒的抗體的研究提供了資金支持。

Research has determined that there is already an effective, though experimental vaccine against Ebola — and it’s being used in Congo — but no studies have indicated what treatments are most effective to treat those who are already infected.

研究已經(jīng)確定，雖然已經(jīng)有一種有效的抗埃博拉病毒的實驗疫苗，而且該疫苗正在剛果使用，但是沒有研究表明哪種治療方法對那些已經(jīng)感染埃博拉病毒的人最有效。

During the outbreak in West Africa several years ago, studies pointed to an antibody mixture known as ZMapp, but its effectiveness has yet to be clearly proven.

幾年前在西非爆發(fā)期間，研究指出一種稱為ZMAPP的抗體混合物，但其有效性尚未得到明確證明。

So in Congo, researchers decided to compare ZMapp to the Regeneron compound, the one developed by the NIH, called mAb114, and an antiviral drug known as remdesivir.

因此，在剛果，研究人員決定將ZMAPP，與由國家衛(wèi)生研究院開發(fā)的一種叫做MAB114的化合物Regeneron，和一種叫做Remdisivr的抗病毒藥物進行比較。

A panel determined that the Regeneron compound was clearly the most effective in fighting Ebola, with the NIH antibody a close second, Dr. Anthony Fauci of the NIH told the Associated Press on Monday.

周一，美國國立衛(wèi)生研究院的安東尼·福奇博士對美聯(lián)社說，一個小組認為，該化合物顯然是最有效的抗埃博拉病毒藥物，NIH抗體緊隨其后。

The research revealed that far fewer Ebola patients died among those given either the Regeneron drug or the NIH’s — about 30 percent compared to half under the ZMapp treatment.

研究表明，在服用了再生成素或NIH的患者中，死于埃博拉病毒的患者要少大約30%，而在ZMAPP治療的患者中，這一比例可以達到50%。

Remarkably, when clients sought care before too much virus spread into their bloodstream, the mortality rate was a mere 6 percent with the Regeneron drug and 11 percent with the NIH’s. The mortality rate for those using ZMapp under the same circumstances was 24 percent.

值得注意的是，當病人在病毒大量進入血液之前接受治療時，使用再生藥物的死亡率僅為6%，而NIH的死亡率為11%。在相同情況下，使用ZMapp的患者的死亡率為24%。

The evidence was strong enough to call a halt to the trial — and to prioritize the use of those two drugs in Congo.

有足夠的證據(jù)要求停止這項試驗，并優(yōu)先考慮在剛果使用這兩種藥物。